Introduction {#sec1-2045894018786696}
============

Hereditary hemorrhagic telangiectasia (HHT), also known as Rendu-Osler-Weber disorder, is an autosomal dominant disease affecting approximately 1:5000.^[@bibr1-2045894018786696][@bibr2-2045894018786696][@bibr3-2045894018786696][@bibr4-2045894018786696]--[@bibr5-2045894018786696]^ The disease is characterized by mucocutaneous telangiectasia and arteriovenous malformations (AVMs) in several organs, but primarily affecting the lungs, gastrointestinal tract, and brain.^[@bibr6-2045894018786696][@bibr7-2045894018786696][@bibr8-2045894018786696][@bibr9-2045894018786696]--[@bibr10-2045894018786696]^ The majority of cases of HHT are due to germline mutations in the endoglin (ENG) gene, activin receptor-like kinase1 (ALK1) gene, and SMAD family 4 (SMAD4) gene, referred to as HHT type 1 (HHT1), type 2 (HHT2), and type 3 (HHT3), respectively.^[@bibr11-2045894018786696][@bibr12-2045894018786696][@bibr13-2045894018786696]--[@bibr14-2045894018786696]^ All three genes are involved in TGFb signaling.

HHT is clinically diagnosed based on the Curaçao criteria, which include recurrent epistaxis, telangiectasia, visceral AVMs, and a first-degree family member with HHT.^[@bibr15-2045894018786696]^ While epistaxis is the most common presenting symptom in adults, almost half of patients remain asymptomatic until adulthood, making diagnosis in childhood challenging.^[@bibr7-2045894018786696],[@bibr16-2045894018786696][@bibr17-2045894018786696][@bibr18-2045894018786696]--[@bibr19-2045894018786696]^ The more concerning clinical aspect of HHT is the presence of AVMs. Patients with large visceral AVMs may suffer significant morbidity and even death. Pulmonary AVMs (PAVMs) are the most common AVMs seen in patients with HHT and have been associated with debilitating and life-threatening complications such as stroke, cerebral abscess, massive hemoptysis, and hemothorax. While these complications have been reported predominantly in the adult population, they are also known to occur albeit less frequently in pediatric HHT cohorts^[@bibr20-2045894018786696][@bibr21-2045894018786696][@bibr22-2045894018786696][@bibr23-2045894018786696]--[@bibr24-2045894018786696]^ where the prevalence of PAVMs approaches that in adults. Symptoms such as shortness of breath, exercise intolerance, clubbing, cyanosis, and hemoptysis may lead to the diagnosis of PAVMs in children; however, more than half (56%) of children diagnosed with PAVMs may be asymptomatic at the time of detection.^[@bibr19-2045894018786696]^

While the prevalence of PAVMs reported in children approaches the rate reported in adults, questions regarding the natural history of PAVMs in children remain largely unknown: Are children with HHT at risk for developing PAVMs at any age and what identifiable risk factors might they have? If children have no or minimal PAVMs at initial diagnosis of their HHT, what risk do they have for the subsequent development of PAVMs and/or their worsening? Finally, how often do PAVMs progress to the point of needing intervention and perhaps even several interventions? The answers to these questions have obvious implications for counseling families and setting expectations regarding future follow-up care. This 14-year longitudinal study of 129 children with HHT is one of the largest and longest studies to date designed to help provide answers to these questions.

Methods {#sec2-2045894018786696}
=======

Patient population and study design {#sec3-2045894018786696}
-----------------------------------

This study was approved by the Washington University Institutional Review Board; given the retrospective nature of the review, informed consent was waived. The medical records of 197 pediatric patients referred for evaluation of HHT from May 2002 through December 2016 were reviewed. Patients diagnosed with definite HHT were included in the study. HHT was diagnosed clinically by fulfilling ≥ 3 Curaçao criteria and/or confirmed with genetic testing. Curaçao criteria include recurrent spontaneous epistaxis, cutaneous telangiectasia, visceral arteriovenous malformations, and a first-degree relative with confirmed HHT.^[@bibr15-2045894018786696]^ Patients with suspected or unlikely clinical diagnosis (Curaçao criteria \<3) were excluded. Genetic testing was offered to all patients with possible or suspected HHT.

A review of the medical record was performed to identify information regarding patient characteristics such as age at diagnosis of HHT, sex, genetic mutation, prevalence of pulmonary AVMs, and clinical symptoms. Primary outcomes evaluated included the prevalence of PAVMs on initial screening, freedom from PAVM over time, incidence of PAVM-related complications, and treatment with embolization.

Screening, diagnosis, and treatment of PAVMs {#sec4-2045894018786696}
--------------------------------------------

Transthoracic contrast echocardiography (TTCE) was the initial screening method for the presence of PAVMs in all patients in the study. PAVMs were diagnosed in the absence of intracardiac shunting based on Barzilai criteria.^[@bibr25-2045894018786696]^ New PAVMs were diagnosed by a positive TTCE after a previous negative TTCE. A positive TTCE with a moderate degree of microcavitations (Barzilai criteria ≥ 2) was confirmed with contrast-enhanced chest CT. Once PAVMs were monitored with chest computed tomography (CT), this became the primary modality for serial evaluation.

Simple PAVMs were defined by one or more afferent feeding arteries originating from a single segmental pulmonary artery, and complex PAVMs were characterized by multiple afferent feeding arteries originating from several segmental arteries. PAVMs were considered large when the feeding artery diameter was ≥3 mm.

Patients with no or small PAVMs were followed with serial screening every five years. Large PAVMs were referred for transcatheter embolization. After embolization, follow-up assessments occurred annually or biannually, and included chest CT. When reperfusion of the PAVM was suspected, pulmonary angiography was performed.

Statistical analysis {#sec5-2045894018786696}
--------------------

Differences between the groups were assessed with Chi-squared analysis for discrete variables and T-test for continuous variables. *P* \< 0.05 was considered statistically significant. Statistical analysis was performed with SPSS version 24.

Results {#sec6-2045894018786696}
=======

In total, 197 patients were evaluated for HHT between May 2002 and December 2016; of these, 129 were diagnosed with definite HHT. Fifty-five of the patients had at least one sibling included in the cohort. All patients were offered genetic testing; out of the 129 patients, 80 chose to undergo genetic testing. The primary reasons families chose to decline were lack of insurance coverage and fear of increased insurance premiums in the future do to a pre-existing medical condition. Of the 80 children genetically tested, 77 were found to have mutations consistent with HHT. Sixty-two patients had HHT 1 (ENG mutation), 11 HHT 2 (ALK1 mutation), and four had HHT 3 (SMAD4 mutation). The demographic and clinical features of the 129 patients with HHT are shown in [Table 1](#table1-2045894018786696){ref-type="table"}. Table 1.Demographic and clinical features of pediatric patients with HHT (n = 129).Age at diagnosis (years)8.77 ± 5.02Sex ratio, males66 (51)Genetically confirmed77 (60) *ENG* mutation, HHT 162 (81) *ALK1* mutation, HHT 211 (14) *SMAD4* mutation, HHT 34 (5)Curaçao criteria Epistaxis119 (92) Telangiectasia103 (80) Family history121 (94) Visceral involvement81 (63)Diagnosis based on Genetics17 (36) Curaçao50(39) Both62 (48)Pulmonary involvement PAVMs[\*](#table-fn2-2045894018786696){ref-type="table-fn"}76 (59) Small38 (29.5) Large38 (29.5) Simple60 (46.5) Complex15 (11.6)Symptomatic PAVMs^[†](#table-fn3-2045894018786696){ref-type="table-fn"}^15 (11.6) Respiratory symptoms  (exercise intolerance, cyanosis,  hemoptysis, chest pain, SOB)12 (9.3) Cardiac symptoms (MI)^[‡](#table-fn4-2045894018786696){ref-type="table-fn"}^1 (0.8) Neurologic symptoms (embolic stroke)^[‡](#table-fn4-2045894018786696){ref-type="table-fn"}^2 (1.6)Embolotherapy^[§](#table-fn5-2045894018786696){ref-type="table-fn"}^38 (29.5)[^1][^2][^3][^4][^5][^6]

Fifty-nine percent (76/129) of patients had evidence of PAVMs either at the time of their HHT diagnosis or upon subsequent follow-up. The mean age of PAVM detection was approximately nine years. There was no significant trend in detection with age, suggesting that PAVMs may arise at any age ([Fig. 1](#fig1-2045894018786696){ref-type="fig"}). Half of the 76 children diagnosed with PAVMs had their lesions characterized as small, the other half large. None of the 38 children with small PAVMs were symptomatic from their lesions. Interestingly, 23 (60%) of the children diagnosed with large PAVMs were also asymptomatic. The other 15 (40%) children found to have large PAVMs had symptoms secondary to their vascular lesions, which included exercise intolerance, cyanosis, hemoptysis, chest pain, shortness of breath, embolic strokes, and cardiac ischemia. All 38 children with large PAVMs underwent embolization therapy. Thus, PAVMs can occur at any age and even those with large lesions may have no symptoms. Fig. 1.Prevalence of pulmonary arteriovenous malformation by age at diagnosis of HHT.

As noted above and shown in [Fig. 2](#fig2-2045894018786696){ref-type="fig"}, the overall prevalence of PAVMs in the 129 children with HHT followed over our 14-year observational period was ∼ 60% (n = 76). Almost 90% (67) of the children with PAVMs in this study were diagnosed at the time of initial screening. Of the 62 children without PAVMs on initial screening, 31 were followed for \> 1 year. Notably, nine of these 31 children (29%) developed evidence of a new PAVM after the initial negative study (mean time to detection = 5.6 years). The characteristics of the nine children who developed new PAVMs during follow-up are shown in [Table 2](#table2-2045894018786696){ref-type="table"}. New PAVMs were diagnosed by a positive TTCE after a previous negative TTCE, and a moderately positive TTCE (Barzilai criteria ≥ 2) was confirmed with contrast-enhanced chest CT. On average, these patients were younger, with a mean age at diagnosis of 5.3 years compared to the overall mean age at time of detection of approximately nine years. All were asymptomatic at the time of detection and only one had large PAVMs. Thus, while most HHT children who develop PAVMs will have their PAVMs discovered at the same time as their HHT diagnosis, ∼ 30% will develop PAVMs at a later date. Fig. 2.Flow chart depicting PAVM prevalence and treatment over time. Table 2.Nine patients who developed PAVMs after initial negative screen.Age at diagnosis (years)GenderGeneticsTime to PAVM detection (years)EmbolotherapyAge at embolization (years)Duration of follow-up (years)3MNone found3No106M-1No44MENG1No71FENG7Yes8126FENG3No37FENG4No913FNone found3No33M-6No65FENG1No1[^7]

Having a genetic diagnosis, age at HHT diagnosis, and gender were not associated with risk of having PAVM ([Table 3](#table3-2045894018786696){ref-type="table"}). The majority of patients with HHT type 2 did not have PAVMs, and this difference was statistically significant (*P* = 0.005). Of note, none of the children developed indirect of evidence for pulmonary hypertension based on screening echocardiograms. Table 3.Comparison of demographic variables between patients who developed PAVMs.PAVMs (n = 76)No PAVMs (n = 54)*P* valueAge (years)8.7 ± 4.79.7 ± 5.490.916Male sex40/76 (53)24/54 (44)0.85Genetics HHT 140/76 (53)24/54 (39)0.12 HHT 22/76 (3)9/54 (16)0.005[\*](#table-fn9-2045894018786696){ref-type="table-fn"} HHT 31/76 (1)3/54 (6)0.017[^8][^9]

Of the 76 children diagnosed with PAVMs, 38 (50%) had lesions described as large and all were treated with embolization. Median age at embolization was 10 ± 5 years. Most (n = 29) of these 38 children were treated after their initial screening for HHT. The other nine (24%), however, had PAVMs that were too small to treat at the time of their HHT diagnosis but subsequently grew large enough to be treated with embolization at a later time (mean time from PAVM diagnosis to embolization = 3.4 years). After embolization, 21% (8/38) underwent repeat interventions (mean time between embolizations = 4.5 years). The characteristics of the eight patients who were treated with multiple interventions are shown in [Table 4](#table4-2045894018786696){ref-type="table"}. All of these patients had complex PAVMs. The primary reason for repeat intervention was reperfusion to the previously embolized PAVMs. No children suffered complications from having a PAVM or having them embolized. Thus, small PAVMs can become large with time and even those embolized have the potential to reoccur or re-vascularize. Table 4.Characteristics of the eight patients who required multiple embolizations.Age at PAVM diagnosis (years)GeneticsAge at initial embolization (years)Age at re-intervention (years)Type of PAVM[\*](#table-fn10-2045894018786696){ref-type="table-fn"}Reason for re-intervention^[†](#table-fn11-2045894018786696){ref-type="table-fn"}^Total embolizations (n)Duration of follow-up (years)7--812Diffuse bilateral, including several complex PAVMsProgression and reperfusion through new collateral formation472--38Diffuse bilateral, including complex LLL PAVMReperfusion through new collateral formation362ENG26Diffuse right lung, including complex RML PAVMProgression395Alk156Diffuse bilateral, including complex RUL and LLL PAVMsReperfusion through new collateral formation3105--516Complex RML AVMReperfusion through new collateral formation2116ENG610Complex RUL PAVMReperfusion through new collateral formation246--613Complex RML PAVMReperfusion through new collateral formation and through previously placed coils3125ENG715Complex RLL PAVMReperfusion through new collateral formation214[^10][^11][^12]

Discussion {#sec7-2045894018786696}
==========

In this 14-year longitudinal study of 129 children with HHT, it was found that PAVMs occur at practically any age with a prevalence of nearly 60%. While most PAVMs were diagnosed at the same time as their initial HHT screening, this study demonstrates that ∼30% of children who were initially negative for PAVMs subsequently developed them within five years. The PAVM prevalence of 60% is slightly higher than that reported in other pediatric studies to date (22--52%),^[@bibr14-2045894018786696],[@bibr26-2045894018786696][@bibr27-2045894018786696][@bibr28-2045894018786696][@bibr29-2045894018786696][@bibr30-2045894018786696][@bibr31-2045894018786696]--[@bibr32-2045894018786696]^ which may be secondary to the longitudinal nature of our study and that fact that new PAVMs do, in fact, develop over time. Also, a referral bias may be at play in patients seen at an HHT Center. In addition, it was noted that ∼25% of children whose PAVMs were considered too small to require embolization at initial screening went on to develop lesions large enough for intervention within 3--5 years. Finally, ∼ 20% of those children who underwent successful embolization received further transcatheter treatment within five years of the original intervention. Reintervention was primarily due to recanalization via collateral vessel formation. All of these observations emphasize the importance that children of any age diagnosed with HHT should be screened for potential PAVMs and that subsequent follow-up is critical regardless of whether PAVMs are absent, small, or embolized. The Washington University HHT Center routinely screens all children every five years for PAVMs using TTCE as the initial imaging modality of choice. In skilled hands, TTCE can be easily obtained on children under the age of five years; while the benefits of intervention in this age group have not been proven, detection of PAVMs is certainly achievable which has potential implications for future management.

The finding that nearly 60% of children with large PAVMs were asymptomatic at the time of initial screening suggests that relying on clinical findings alone may not identify children at risk for significant morbidity. This observation further argues for the importance of PAVM screening in all children with HHT. Using the current practice of screening with TTCE, we have not had any child develop severe complications from undiagnosed PAVMs such as embolic stroke, brain abscess, hemoptysis, or hemothorax. Interestingly, Hosman et al. recently reported similar outcomes with a less invasive approach^[@bibr31-2045894018786696]^ that involves screening with pulse oximetry and chest radiography, utilizing chest CT only for those cases with heightened suspicion for PAVM. They found this approach was similarly successful in preventing serious PAVM-related sequelae.

Compared to other pediatric studies of HHT, not only did we find a higher prevalence of PAVMs in our pediatric cohort of 129 children, but also a higher rate of embolization: 29% of all patients with HHT underwent embolization. Comparatively, in the French series by Soysal^[@bibr32-2045894018786696]^ where all pediatric patients with HHT were screened for PAVM with chest CT (59 patients), only 7% of all children with HHT underwent embolization. Furthermore, the Dutch study of Hosman et al.,^[@bibr31-2045894018786696]^ using a more conservative screening approach designed to detect large PAVMs, reported only a 22% prevalence of PAVMs in 175 children with HHT compared to 60% in our study. Not surprisingly, their overall rates of embolization were also lower than in our series, as embolization was performed in 19% of all patients with HHT.

Limitations of this study include the retrospective nature of the review. The high incidence of PAVM detection may be related to recruitment bias, particularly in symptomatic patients. However, only 11% of our patients were symptomatic at the time of PAVM detection which suggests this effect may be minimal.

Conclusion {#sec8-2045894018786696}
==========

PAVMs are present in up to 60% of children with HHT. Most PAVMs can be detected on initial screening with TTCE, but nearly 30% of children with HHT can develop new PAVMs over time. Furthermore, up to 25% of children initially diagnosed with small PAVMs can develop larger PAVMs requiring embolization. The majority of children with large PAVMs have no symptoms from their lesions. Finally, nearly 20% of those children who had successful embolization therapy needed repeat intervention. Children diagnosed with HHT need continued assessment for PAVMs throughout childhood.
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[^1]: Continuous data are shown as mean ± SD, and categorical data as number (%).

[^2]: Large PAVM: at least one large PAVM (feeding artery ≥ 3 mm). Small PAVM: feeding artery ≤ 3 mm. Simple PAVM: one or more afferent feeding arteries originating from a single segmental pulmonary artery. Complex PAVM: multiple afferent feeding arteries originating from several segmental arteries.

[^3]: All of the symptomatic patients had large PAVMs.

[^4]: MI and embolic stroke were the presenting symptoms for 1 and 2 patients, respectively.

[^5]: Treatment was only considered for large PAVMs.

[^6]: PAVM, pulmonary AVM; MI, myocardial infarction; CVM, cerebrovascular malformation; ICH, intracranial hemorrhage; SOB, shortness of breath.

[^7]: M, male; F, female; ENG, endoglin mutation; PAVM, pulmonary arteriovenous malformation.

[^8]: Continuous data are shown as mean ± SD, and categorical data as number (%).

[^9]: *P* value \< 0.05 considered statistically significant.

[^10]: Complex PAVM: multiple afferent feeding arteries originating from several segmental arteries.

[^11]: Progression: increase in size of feeding vessel diameter of existing PAVMs. Reperfusion: recanalization of previously embolized PAVM.

[^12]: PAVM, pulmonary arteriovenous malformation; LLL, left lower lobe; RML, right middle lobe; RUL, right upper lobe; RLL, right lower lobe.
